Association of serum Dkk-1 levels with β-catenin in patients with postmenopausal osteoporosis.

J Huazhong Univ Sci Technolog Med Sci

Department of Integrated Traditional Chinese Medicine and Western Medicine, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.

Published: April 2015


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Wnt signaling plays an important role in the bone development and remodeling. The Wnt antagonist Dkk-1 is a potent inhibitor of bone formation. The aims of this study were firstly to compare the serum Dkk-1 levels in postmenopausal osteoporosis patients with age-matched healthy controls, and secondly, to assess the possible relationship between Dkk-1 and β-catenin, sclerostin, or bone turnover markers [CTX, PINP, N-MID-OT and 25(OH)D] in the setting of postmenopausal osteoporosis. A total of 350 patients with postmenopausal osteoporosis and 150 age-matched healthy controls were enrolled, and the serum levels of Dkk-1, β-catenin, sclerostin, OPG, and RANKL were detected by ELISA, and bone turnover markers [CTX, PINP, N-MID-OT and 25(OH)D] were measured by Roche electrochemiluminescence system in two groups. Serum Dkk-1 levels were significantly higher in postmenopausal osteoporosis group than in control group (P<0.001). Univariate analyses revealed that serum Dkk-1 levels were weakly negatively correlated to β-catenin (r=-0.161, P=0.003) and OPG (r=-0.106, P=0.047), while multiple regression analysis showed a negative correlation between serum Dkk-1 levels with β-catenin (β=-0.165, P=0.009) and BMD (β=-0.139, P=0.027), and a positive correlation between serum Dkk-1 levels and CTX (β=0.122, P=0.040) in postmenopausal osteoporosis group. No similar correlations ware observed in control group. The results provided evidence for the role of Dkk-1 in bone metabolism and demonstrated the link of Dkk-1 and Wnt/β-catenin in some ways.

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11596-015-1413-6DOI Listing

Publication Analysis

Top Keywords

postmenopausal osteoporosis
20
serum dkk-1
12
dkk-1 levels
12
patients postmenopausal
8
age-matched healthy
8
healthy controls
8
dkk-1 β-catenin
8
β-catenin sclerostin
8
bone turnover
8
turnover markers
8

Similar Publications

Unlabelled: Dual-energy x-ray absorptiometry (DXA)-derived areal bone mineral density (BMD) remains the clinical standard for assessing osteoporosis risk, yet it fails to identify over 75% of individuals who sustain fragility fractures. Direct in vivo mechanical assessment of cortical bone strength may address this diagnostic gap by capturing structural and material properties that govern whole-bone strength but are not reflected by BMD. We conducted a multicenter case-control study with cross-sectional assessment to compare ulna flexural rigidity, a biomechanical property correlated with whole-bone strength (R² ≈ 0.

View Article and Find Full Text PDF

Postmenopausal osteoporosis increases periodontal inflammation and the pathogenicity of the oral microbiota in a rat model.

J Oral Microbiol

September 2025

Chongqing Key Laboratory for Oral Diseases and Biomedical Sciences, Chongqing Municipal Key Laboratory for Oral Biomedical Engineering of Higher Education, and Stomatological Hospital of Chongqing Medical University, Chongqing, China.

Objectives: This study aims to explore the mechanisms of the detrimental effects of postmenopausal osteoporosis (PMO) on periodontitis.

Methods: An ovariectomized (OVX) rat model was established to investigate the effects of PMO on alveolar bone homeostasis and periodontal inflammation. Chlorhexidine digluconate (CHX) was administered to rats with OVX - periodontitis to ascertain the involvement of the oral microbiota in the influence of PMO on periodontitis.

View Article and Find Full Text PDF

Introduction: Odanacatib (ODN), a cathepsin K inhibitor, is a drug that reduces bone resorption while preserving bone formation. ODN was initially developed for the treatment of postmenopausal osteoporosis, but further development as a systemic medication has been discontinued. Here, we propose ODN as a topical treatment, the coating of dental implants, to achieve an anabolic shift of early osseointegration.

View Article and Find Full Text PDF

A novel HDAC1-specific inhibitor prevents estrogen deficiency-induced osteoporosis in mice by inhibiting osteoclast function.

Arch Gerontol Geriatr

August 2025

Department of Orthopedics Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; Orthopedics Research Institute of Zhejiang University, Hangzhou 310009, China; Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Provinc

Postmenopausal osteoporosis (PMOP) features reduced bone mass and deteriorated bone microstructure, increasing fracture risk. Estrogen deficiency-induced osteoclast overactivation is a primary driver. OCP-001, a novel highly selective HDAC1 inhibitor, was investigated.

View Article and Find Full Text PDF

Postmenopausal osteoporosis (PMOP) is a common primary osteoporosis. With the aging of the population, it is becoming a major disease that endangers health and quality of life. The purpose of this study was to explore the effect of gut microbiota on PMOP by observing the changes in the levels of estradiol, bone density, and gut microbiota diversity in rats after 3 months of OVX surgery.

View Article and Find Full Text PDF